{"id":222537,"date":"2025-09-26T08:08:14","date_gmt":"2025-09-26T13:08:14","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2025\/09\/unique-pan-cancer-immunotherapy-destroys-tumors-without-attacking-healthy-tissue"},"modified":"2025-09-26T08:08:14","modified_gmt":"2025-09-26T13:08:14","slug":"unique-pan-cancer-immunotherapy-destroys-tumors-without-attacking-healthy-tissue","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2025\/09\/unique-pan-cancer-immunotherapy-destroys-tumors-without-attacking-healthy-tissue","title":{"rendered":"Unique pan-cancer immunotherapy destroys tumors without attacking healthy tissue"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/unique-pan-cancer-immunotherapy-destroys-tumors-without-attacking-healthy-tissue2.jpg\"><\/a><\/p>\n<p>A new, highly potent class of immunotherapeutics with unique Velcro-like binding properties can kill diverse cancer types without harming normal tissue, University of California, Irvine cancer researchers have demonstrated.<\/p>\n<p>A team led by Michael Demetriou, MD, Ph.D., has reported that by targeting cancer-associated complex carbohydrate chains called glycans with binding proteins, they could penetrate the protective shields of tumor cells and trigger their death without toxicity to surrounding tissue.<\/p>\n<p>Their biologically engineered immunotherapies\u2014glycan-dependent T cell recruiter (GlyTR, pronounced \u2018glitter\u2019) compounds, GlyTR1 and GlyTR 2\u2014proved safe and effective in models for a spectrum of cancers, including those of the breast, colon, lung, ovaries, pancreas and prostate, the researchers <a href=\"https:\/\/www.cell.com\/cell\/fulltext\/S0092-8674(25)01032-3\" target=\"_blank\">report<\/a> in the journal <i>Cell<\/i>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A new, highly potent class of immunotherapeutics with unique Velcro-like binding properties can kill diverse cancer types without harming normal tissue, University of California, Irvine cancer researchers have demonstrated. A team led by Michael Demetriou, MD, Ph.D., has reported that by targeting cancer-associated complex carbohydrate chains called glycans with binding proteins, they could penetrate the [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-222537","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/222537","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=222537"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/222537\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=222537"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=222537"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=222537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}